- |||||||||| ABL10X / ABL Bio, utomilumab (PF-05082566) / Pfizer, urelumab (BMS-663513) / BMS, Ono Pharma
[VIRTUAL] A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format () - Mar 11, 2021 - Abstract #AACR2021AACR_3299;
Various TAAx1A10 bispecific antibodies were generated by introducing 1A10 scFv into human IgGs targeting TAA...1A10 binding inhibited further binding of utomilumab to CD137, but not the binding of urelumab or CD137L to CD137, suggesting that the 1A10 binding site is different from urelumab or CD137L...The 1A10 epitope site is partially overlapping with utomilumab binding sites on the CRD4 but does not bind to the CRD3, where utomilumab binds and competes with CD137L. In summary, 1A10, the anti-CD137 antibody with a unique epitope exhibited clustering dependent CD137 activation and potent anti-tumor activity via tumor-specific activation of CD137 in bispecific antibody format.
|
